Observations on the early detection of prostate cancer from the American Cancer Society national prostate cancer detection project

Mettlin, Curtis; Murphy, Gerald P.; Babaian, R. Joseph; Chesley, Arthur; Kane, Robert A.; Littrup, Peter J.; Mostofi, F. K.; Ray, Paul S.; Somers, William J.; Toi, Ants

doi:10.1002/(sici)1097-0142(19971101)80:9<1814::aid-cncr20>3.0.co;2-7

Cited by 50 publications

(40 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, in the screening program of the American Cancer Society National Prostate Cancer Detection Program (ACS-NPCDP), only one of a total of 51 cancers diagnosed at follow-up visits was at a clinically advanced (C2) stage [72]. Hugosson et al [69] have found that 97% of the cancers detected by screening were clinically localized.…”

Section: Combined Androgen Blockade In Advanced Diseasementioning

confidence: 99%

Major impact of hormonal therapy in localized prostate cancer—death can already be an exception

Labrie¹,

Cusan²,

Luu‐The³

et al. 2004

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

Section: Combined Androgen Blockade In Advanced Diseasementioning

confidence: 99%

Major impact of hormonal therapy in localized prostate cancer—death can already be an exception

Labrie¹,

Cusan²,

Luu‐The³

et al. 2004

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

“…As prostate cancer is increasingly being diagnosed in the early stages and, therefore, with more favorable survival outcomes, the basis on which patients select primary therapy has shifted toward considerations of health-related quality of life (HRQOL) (Mettlin et al 1997;Davis et al 2001). Many studies have addressed the eVect of treatments for prostate cancer on HRQOL outcomes, but few have focused on HRQOL in men over the age of 70 years with localized prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Quality of life among elderly men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy

Namiki

Ishidoya

Kawamura

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…1,2 However, no HRQOL instrument has previously been developed and validated in a setting concurrently representing each of the three most common current interventions for localized prostate cancer: radical prostatectomy, external beam radiation, and brachytherapy. 3,4 Moreover, neoadjuvant or adjuvant hormonal therapy is commonly used to complement these primary interventions, yet consequent HRQOL effects have not been sufficiently characterized, largely because of the absence of validated HRQOL scales for measuring androgen-deprivation symptoms and related bother.…”

mentioning

confidence: 99%

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

Wei¹,

Dunn²,

Litwin³

et al. 2000

Urology

1,369

932

View full text Add to dashboard Cite

Objectives. Health-related quality of life (HRQOL) is an increasingly important endpoint in prostate cancer care. However, pivotal issues that are not fully assessed in existing HRQOL instruments include irritative urinary symptoms, hormonal symptoms, and multi-item scores quantifying bother between urinary, sexual, bowel, and hormonal domains. We sought to develop a novel instrument to facilitate more comprehensive assessment of prostate cancer-related HRQOL. Methods. Instrument development was based on advice from an expert panel and prostate cancer patients, which led to expanding the 20-item University of California-Los Angeles Prostate Cancer Index (UCLA-PCI) to the 50-item Expanded Prostate Index Composite (EPIC). Summary and subscale scores were derived by content and factor analyses. Reliability and validity were assessed by test-retest correlation, Cronbach's alpha coefficient, interscale correlation, and EPIC correlation with other validated instruments. Results. Test-retest reliability and internal consistency were high for EPIC urinary, bowel, sexual, and hormonal domain summary scores (each r Ն0.80 and Cronbach's alpha Ն0.82) and for most domain-specific subscales. Correlations between function and bother subscales within domains were high (r Ͼ0.60). Correlations between different primary domains were consistently lower, indicating that these domains assess distinct HRQOL components. EPIC domains had weak to modest correlations with the Medical Outcomes Study 12-item Short-Form Health Survey (SF-12), indicating rationale for their concurrent use. Moderate agreement was observed between EPIC domains relevant to the Functional Assessment of Cancer Therapy Prostate module (FACT-P) and the American Urological Association Symptom Index (AUA-SI), providing criterion validity without excessive overlap. Conclusions. EPIC is a robust prostate cancer HRQOL instrument that complements prior instruments by measuring a broad spectrum of urinary, bowel, sexual, and hormonal symptoms, thereby providing a unique tool for comprehensive assessment of HRQOL issues important in contemporary prostate cancer management. A s prostate cancer is increasingly diagnosed at early stages with favorable survival outcomes, the basis on which patients select primary therapy has shifted toward consideration of health-related quality of life (HRQOL). 1,2 However, no HRQOL instrument has previously been developed and validated in a setting concurrently representing each of the three most common current interventions Supported by National Institutes of Health grants 5P30CA46598 and 1P50CA69568 (National Cancer Institute Prostate Cancer Specialized Projects of Oncology Research Excellence [SPORE]), American Cancer Society Clinical Career Development Award 96-77 (M.G.S.), Robert Wood Johnson Scholars Program (J.T.W.), and American Foundation for Urological Diseases Fellowship Award (J.T.W.). From the Veterans Affairs Center for Practice Management and Outcomes Research; Ann Arbor Veterans Affairs Medical

show abstract

Observations on the early detection of prostate cancer from the American Cancer Society national prostate cancer detection project

Cited by 50 publications

References 11 publications

Major impact of hormonal therapy in localized prostate cancer—death can already be an exception

Major impact of hormonal therapy in localized prostate cancer—death can already be an exception

Quality of life among elderly men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

Contact Info

Product

Resources

About